Claims
- 1. A method of increasing the volume of distribution of a nucleic acid encoding a therapeutic agent in a tissue in a subject during localized delivery, comprising administering to the tissue in the subject a nucleic acid encoding a therapeutic agent and a facilitating agent, whereby the inclusion of the facilitating agent increases the volume of distribution of the nucleic acid encoding a therapeutic agent in the tissue.
- 2. The method of claim 1, wherein the localized delivery is selected from the group consisting of hypodermic injection, convection enhanced delivery, intracerebral injection and intraventricular injection.
- 3. The method of claim 1, wherein the nucleic acid is an AAV2 vector.
- 4. The method of claim 1, wherein the facilitating agent is heparin.
- 5. A method of treating a neurodegenerative disorder in a subject in need of such treatment, comprising administering to the subject a nucleic acid encoding a therapeutic agent and a facilitating agent, wherein the nucleic acid encoding a therapeutic agent and the facilitating agent are administered via localized delivery.
- 6. The method of claim 5, wherein the localized delivery is selected from the group consisting of convection enhanced delivery, hypodermic injection, intracerebral injection and intraventricular injection.
- 7. The method of claim 5, wherein the neurodegenerative disorder is Parkinson's disease.
- 8. The method of claim 5, wherein the nucleic acid is an AAV2 vector.
- 9. The method of claim 5, wherein the facilitating agent is heparin.
Parent Case Info
[0001] This application claims priority from provisional patent application Serial No. 60/286,308, filed Apr. 25, 2001 which is hereby incorporated in its entirety by this reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60286308 |
Apr 2001 |
US |